RU2002111344A - A quinuclidine compound and a medicament containing the compound as an active ingredient - Google Patents
A quinuclidine compound and a medicament containing the compound as an active ingredientInfo
- Publication number
- RU2002111344A RU2002111344A RU2002111344/04A RU2002111344A RU2002111344A RU 2002111344 A RU2002111344 A RU 2002111344A RU 2002111344/04 A RU2002111344/04 A RU 2002111344/04A RU 2002111344 A RU2002111344 A RU 2002111344A RU 2002111344 A RU2002111344 A RU 2002111344A
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- groups
- halogenated
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- -1 quinuclidine compound Chemical class 0.000 title claims 17
- 239000003814 drug Substances 0.000 title claims 8
- 239000004480 active ingredient Substances 0.000 title 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 70
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 50
- 125000005843 halogen group Chemical group 0.000 claims 44
- 125000003277 amino group Chemical group 0.000 claims 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 30
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 27
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 26
- 125000002252 acyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 239000004215 Carbon black (E152) Substances 0.000 claims 20
- 229930195733 hydrocarbon Natural products 0.000 claims 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 19
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 150000002430 hydrocarbons Chemical class 0.000 claims 15
- 125000002560 nitrile group Chemical group 0.000 claims 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 10
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 9
- 125000005108 alkenylthio group Chemical group 0.000 claims 9
- 125000005109 alkynylthio group Chemical group 0.000 claims 9
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 5
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 4
- APKABZVBYAUJOF-UHFFFAOYSA-N 2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CN2CCC1C(O)C2C#C APKABZVBYAUJOF-UHFFFAOYSA-N 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229940031439 squalene Drugs 0.000 claims 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 3
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 3
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 230000002194 synthesizing effect Effects 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 150000001555 benzenes Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- UQUKUFHHSGWAQT-DEGQGPPLSA-N (3R)-1-[6-benzyl-5-[(3R)-2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]pyridin-2-yl]-3-hydroxypyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C([C@@H](CC1)O)=O UQUKUFHHSGWAQT-DEGQGPPLSA-N 0.000 claims 1
- QXSQOJNLKWRNCE-NAMMGXCXSA-N (3R)-1-[6-benzyl-5-[(3R)-2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]pyridin-2-yl]-3-methoxypyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C([C@@H](CC1)OC)=O QXSQOJNLKWRNCE-NAMMGXCXSA-N 0.000 claims 1
- DSILBMFOANERAA-FXDYGKIASA-N (3R)-3-(4-benzyl-6-pyridin-2-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1[C@]1(C(N2CCC1CC2)C#C)O)C1=NC=CC=C1 DSILBMFOANERAA-FXDYGKIASA-N 0.000 claims 1
- FUMSBDHHRMXBLT-NSCXQCAOSA-N (3R)-3-[2-benzyl-5-bromo-6-[(3R,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=C(C=C1[C@]1(C(N2CCC1CC2)C#C)O)Br)N1C[C@H]([C@@H](C1)OC)O FUMSBDHHRMXBLT-NSCXQCAOSA-N 0.000 claims 1
- ZRFARZVJNFRGHV-LFHRXCRSSA-N (3R)-3-[2-benzyl-5-chloro-6-(1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=C(C=C1[C@]1(C(N2CCC1CC2)C#C)O)Cl)N1CC2(CC1)OCCO2 ZRFARZVJNFRGHV-LFHRXCRSSA-N 0.000 claims 1
- CAORKNFPKBBGLL-NSCXQCAOSA-N (3R)-3-[2-benzyl-5-chloro-6-[(3R,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=C(C=C1[C@]1(C(N2CCC1CC2)C#C)O)Cl)N1C[C@H]([C@@H](C1)OC)O CAORKNFPKBBGLL-NSCXQCAOSA-N 0.000 claims 1
- FXXWBSICAPYSHJ-NRWPOFLRSA-N (3R)-3-[2-benzyl-6-(1,3-dioxolan-2-ylmethoxy)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)OCC1OCCO1 FXXWBSICAPYSHJ-NRWPOFLRSA-N 0.000 claims 1
- LXITZIMTNJFFQO-LFHRXCRSSA-N (3R)-3-[2-benzyl-6-(1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1CC2(CC1)OCCO2 LXITZIMTNJFFQO-LFHRXCRSSA-N 0.000 claims 1
- UINUTZHBFUYIPL-OVHROIHKSA-N (3R)-3-[2-benzyl-6-[(3R,4R)-3,4-dimethoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C[C@H]([C@@H](C1)OC)OC UINUTZHBFUYIPL-OVHROIHKSA-N 0.000 claims 1
- LQSXZXRGGAYDHY-NSCXQCAOSA-N (3R)-3-[2-benzyl-6-[(3R,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C[C@H]([C@@H](C1)OC)O LQSXZXRGGAYDHY-NSCXQCAOSA-N 0.000 claims 1
- UINUTZHBFUYIPL-MSKGHIIKSA-N (3R)-3-[2-benzyl-6-[(3R,4S)-3,4-dimethoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C[C@H]([C@H](C1)OC)OC UINUTZHBFUYIPL-MSKGHIIKSA-N 0.000 claims 1
- LQSXZXRGGAYDHY-SVDLFDKWSA-N (3R)-3-[2-benzyl-6-[(3R,4S)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C[C@H]([C@H](C1)OC)O LQSXZXRGGAYDHY-SVDLFDKWSA-N 0.000 claims 1
- ZUFAUYSYRMXCHN-WSMVQKIJSA-N (3R)-3-[2-benzyl-6-[(3S,4R)-3-fluoro-4-methoxypyrrolidin-1-yl]pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C[C@@H]([C@@H](C1)OC)F ZUFAUYSYRMXCHN-WSMVQKIJSA-N 0.000 claims 1
- RYUDLUYIMBJVIR-PLYLYKGUSA-N (3R)-3-[6-(1,3-benzodioxol-5-yl)-4-benzylpyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1[C@]1(C(N2CCC1CC2)C#C)O)C1=CC2=C(C=C1)OCO2 RYUDLUYIMBJVIR-PLYLYKGUSA-N 0.000 claims 1
- WAJUVRBHWXSULW-JDPIBSFWSA-N (3R)-3-[6-benzyl-2-[(3R,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]-2H-pyrimidin-1-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C=1N(C(N=CC=1)N1C[C@H]([C@@H](C1)OC)O)[C@@]1(C(N2CCC1CC2)C#C)O WAJUVRBHWXSULW-JDPIBSFWSA-N 0.000 claims 1
- HHIQFPIZWZFICS-STBCPGIKSA-N (3R,4R)-1-[6-benzyl-5-[(3R)-2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]pyridin-2-yl]-3,4-dimethoxypyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C([C@@H]([C@@H](C1)OC)OC)=O HHIQFPIZWZFICS-STBCPGIKSA-N 0.000 claims 1
- QZFGKSHVOSVFPQ-VSYJZPKMSA-N (3R,4R)-1-[6-benzyl-5-[(3R)-2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]pyridin-2-yl]-4-hydroxy-3-methoxypyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C([C@@H]([C@@H](C1)O)OC)=O QZFGKSHVOSVFPQ-VSYJZPKMSA-N 0.000 claims 1
- HNCAOVUJVKVMIT-FXDYGKIASA-N (3r)-3-(4-benzyl-6-pyridin-3-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1([C@]2(C(N3CCC2CC3)C#C)O)=CN=C(C=2C=NC=CC=2)C=C1CC1=CC=CC=C1 HNCAOVUJVKVMIT-FXDYGKIASA-N 0.000 claims 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- WYZCSRYCAVZKGX-UHFFFAOYSA-N 3-(2-benzyl-6-morpholin-4-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1C1(C(N2CCC1CC2)C#C)O)N1CCOCC1 WYZCSRYCAVZKGX-UHFFFAOYSA-N 0.000 claims 1
- MBSFMDMJGXDZAS-UHFFFAOYSA-N 3-(2-benzyl-6-pyridin-2-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1C1(C(N2CCC1CC2)C#C)O)C1=NC=CC=C1 MBSFMDMJGXDZAS-UHFFFAOYSA-N 0.000 claims 1
- GXWMTPWNSLVKMT-UHFFFAOYSA-N 3-(2-benzyl-6-pyridin-3-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1C1(C(N2CCC1CC2)C#C)O)C=1C=NC=CC=1 GXWMTPWNSLVKMT-UHFFFAOYSA-N 0.000 claims 1
- JGTPEVHAGRHMIY-UHFFFAOYSA-N 3-(3-benzyl-5-phenylpyridin-2-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C=1C(=NC=C(C=1)C1=CC=CC=C1)C1(C(N2CCC1CC2)C#C)O JGTPEVHAGRHMIY-UHFFFAOYSA-N 0.000 claims 1
- WYZPADSIXFKLJX-UHFFFAOYSA-N 3-(3-benzyl-5-pyridin-3-ylpyridin-2-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C=1C(=NC=C(C=1)C=1C=NC=CC=1)C1(C(N2CCC1CC2)C#C)O WYZPADSIXFKLJX-UHFFFAOYSA-N 0.000 claims 1
- SBEKVTAQEDGGSY-UHFFFAOYSA-N 3-(3-benzyl-5-pyridin-4-ylpyridin-2-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C=1C(=NC=C(C=1)C1=CC=NC=C1)C1(C(N2CCC1CC2)C#C)O SBEKVTAQEDGGSY-UHFFFAOYSA-N 0.000 claims 1
- GNCYNSXHZLOPAM-UHFFFAOYSA-N 3-(4-benzyl-2-phenylpyrimidin-5-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C1=CC=CC=C1 GNCYNSXHZLOPAM-UHFFFAOYSA-N 0.000 claims 1
- DSILBMFOANERAA-UHFFFAOYSA-N 3-(4-benzyl-6-pyridin-2-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C1=NC=CC=C1 DSILBMFOANERAA-UHFFFAOYSA-N 0.000 claims 1
- MOETUTMVFHMQIB-UHFFFAOYSA-N 3-(4-benzyl-6-pyridin-4-ylpyridin-3-yl)-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C1=CC=NC=C1 MOETUTMVFHMQIB-UHFFFAOYSA-N 0.000 claims 1
- MGLBHFIHGGCXKR-UHFFFAOYSA-N 3-[2-(1,3-benzodioxol-5-yl)-4-benzylpyrimidin-5-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C1=CC2=C(C=C1)OCO2 MGLBHFIHGGCXKR-UHFFFAOYSA-N 0.000 claims 1
- TXUOULDIWREEEA-UHFFFAOYSA-N 3-[2-(2-benzyl-6-pyridin-4-ylpyridin-3-yl)ethynyl]-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1N(CC2)CCC2C1(O)C#CC1=CC=C(C=2C=CN=CC=2)N=C1CC1=CC=CC=C1 TXUOULDIWREEEA-UHFFFAOYSA-N 0.000 claims 1
- GGVWDUVFTMWMAZ-UHFFFAOYSA-N 3-[2-(3-benzyl-5-pyridin-2-ylpyridin-2-yl)ethynyl]-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1N(CC2)CCC2C1(O)C#CC1=NC=C(C=2N=CC=CC=2)C=C1CC1=CC=CC=C1 GGVWDUVFTMWMAZ-UHFFFAOYSA-N 0.000 claims 1
- NWVMIZSSUUXDDV-UHFFFAOYSA-N 3-[2-[2-benzyl-6-(2-methoxyethoxy)pyridin-3-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol Chemical compound N=1C(OCCOC)=CC=C(C#CC2(O)C3CCN(CC3)C2)C=1CC1=CC=CC=C1 NWVMIZSSUUXDDV-UHFFFAOYSA-N 0.000 claims 1
- ICNOVGPWMZQQDX-UHFFFAOYSA-N 3-[2-[3-benzyl-5-(3-hydroxybutyl)pyridin-2-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C=1C(CCC(O)C)=CN=C(C#CC2(O)C3CCN(CC3)C2)C=1CC1=CC=CC=C1 ICNOVGPWMZQQDX-UHFFFAOYSA-N 0.000 claims 1
- TXPLBEPBQCSQHJ-UHFFFAOYSA-N 3-[2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1C1(C(N2CCC1CC2)C#C)O)OCCCOC TXPLBEPBQCSQHJ-UHFFFAOYSA-N 0.000 claims 1
- AIEAQQIDCFUQHQ-UHFFFAOYSA-N 3-[2-benzyl-6-(3-methoxypropylamino)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1C1(C(N2CCC1CC2)C#C)O)NCCCOC AIEAQQIDCFUQHQ-UHFFFAOYSA-N 0.000 claims 1
- AHHRWOXSNFVLHA-UHFFFAOYSA-N 3-[2-benzyl-6-(4-methoxypiperidin-1-yl)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC(OC)CCN1C1=CC=C(C2(O)C(N3CCC2CC3)C#C)C(CC=2C=CC=CC=2)=N1 AHHRWOXSNFVLHA-UHFFFAOYSA-N 0.000 claims 1
- WCSCVPHOOAJENB-UHFFFAOYSA-N 3-[4-benzyl-6-(2-methoxyethoxy)pyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)OCCOC WCSCVPHOOAJENB-UHFFFAOYSA-N 0.000 claims 1
- RYUDLUYIMBJVIR-UHFFFAOYSA-N 3-[6-(1,3-benzodioxol-5-yl)-4-benzylpyridin-3-yl]-2-ethynyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C1=CC2=C(C=C1)OCO2 RYUDLUYIMBJVIR-UHFFFAOYSA-N 0.000 claims 1
- MNYLJOBAJIIWQH-IGSUDFNFSA-N 3-[6-benzyl-5-(2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)-4-oxo-1H-pyridin-2-yl]propyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1C1(C(N2CCC1CC2)C#C)O)O)CCCOC([C@@H](NC(=O)OC(C)(C)C)C)=O MNYLJOBAJIIWQH-IGSUDFNFSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- ATTYLDRYXWLFOH-UHFFFAOYSA-N 4-O-[3-[6-benzyl-5-(2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)-4-oxo-1H-pyridin-2-yl]propyl] 1-O-methyl butanedioate Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1C1(C(N2CCC1CC2)C#C)O)O)CCCOC(CCC(=O)OC)=O ATTYLDRYXWLFOH-UHFFFAOYSA-N 0.000 claims 1
- OQSCNVBKDFAVOZ-UHFFFAOYSA-N 4-[5-benzyl-6-(2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)pyridin-3-yl]butan-2-one Chemical compound C(C1=CC=CC=C1)C=1C(=NC=C(C=1)CCC(C)=O)C1(C(N2CCC1CC2)C#C)O OQSCNVBKDFAVOZ-UHFFFAOYSA-N 0.000 claims 1
- MDDRCYFYADOGGW-IQHZPMLTSA-N 7-[6-benzyl-5-[(3R)-2-ethynyl-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]pyridin-2-yl]-1,4-dioxa-7-azaspiro[4.4]nonan-6-one Chemical compound C(C1=CC=CC=C1)C1=NC(=CC=C1[C@]1(C(N2CCC1CC2)C#C)O)N1C(C2(CC1)OCCO2)=O MDDRCYFYADOGGW-IQHZPMLTSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- HNCAOVUJVKVMIT-UHFFFAOYSA-N C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C=1C=NC=CC=1 Chemical compound C(C1=CC=CC=C1)C1=CC(=NC=C1C1(C(N2CCC1CC2)C#C)O)C=1C=NC=CC=1 HNCAOVUJVKVMIT-UHFFFAOYSA-N 0.000 claims 1
- MIWLTUOAPQGFTC-XSWBTSGESA-N C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@@]1(C(N2CCC1CC2)C#C)O)O)CCCOC Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@@]1(C(N2CCC1CC2)C#C)O)O)CCCOC MIWLTUOAPQGFTC-XSWBTSGESA-N 0.000 claims 1
- YCUIEOTVRHOEIO-GITCGBDTSA-N C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCF Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCF YCUIEOTVRHOEIO-GITCGBDTSA-N 0.000 claims 1
- BBYHSXCHSQFCSH-GITCGBDTSA-N C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCO Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCO BBYHSXCHSQFCSH-GITCGBDTSA-N 0.000 claims 1
- MIWLTUOAPQGFTC-YNMFNDETSA-N C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCOC Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCCOC MIWLTUOAPQGFTC-YNMFNDETSA-N 0.000 claims 1
- DSWKUJQPPVNPRK-GITCGBDTSA-N C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCOC Chemical compound C(C1=CC=CC=C1)C1=NC(=CC(=C1[C@]1(C(N2CCC1CC2)C#C)O)O)CCOC DSWKUJQPPVNPRK-GITCGBDTSA-N 0.000 claims 1
- KDHAKPZNQVPDDN-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C(=NC=C(C=1)CCC(=O)OCC)C1(C(N2CCC1CC2)C#C)O Chemical compound C(C1=CC=CC=C1)C=1C(=NC=C(C=1)CCC(=O)OCC)C1(C(N2CCC1CC2)C#C)O KDHAKPZNQVPDDN-UHFFFAOYSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- YYIYZXJBNNVZAD-UHFFFAOYSA-N ethyl 1-[6-benzyl-5-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]pyridin-2-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(N=C1CC=2C=CC=CC=2)=CC=C1C#CC1(O)C(CC2)CCN2C1 YYIYZXJBNNVZAD-UHFFFAOYSA-N 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Claims (32)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27390599 | 1999-09-28 | ||
| JP11/273905 | 1999-09-28 | ||
| JP2000/179352 | 2000-06-15 | ||
| JP2000179352 | 2000-06-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002111344A true RU2002111344A (en) | 2003-12-20 |
| RU2266905C2 RU2266905C2 (en) | 2005-12-27 |
Family
ID=26550809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002111344/04A RU2266905C2 (en) | 1999-09-28 | 2000-09-27 | Quinuclidine compounds, medicinal agents comprising thereof and methods for preparing quinuclidine compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6599917B1 (en) |
| EP (1) | EP1217001B1 (en) |
| JP (1) | JP4206212B2 (en) |
| KR (1) | KR100694687B1 (en) |
| CN (1) | CN100334085C (en) |
| AT (1) | ATE312100T1 (en) |
| AU (1) | AU782114B2 (en) |
| BR (1) | BR0014331A (en) |
| CA (1) | CA2385995C (en) |
| DE (1) | DE60024651T2 (en) |
| DK (1) | DK1217001T3 (en) |
| ES (1) | ES2252063T3 (en) |
| HU (1) | HUP0203514A3 (en) |
| IL (2) | IL148631A0 (en) |
| MX (1) | MXPA02003167A (en) |
| NO (1) | NO328218B1 (en) |
| NZ (1) | NZ517788A (en) |
| RU (1) | RU2266905C2 (en) |
| TW (1) | TWI282794B (en) |
| WO (1) | WO2001023383A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| EP1375496B1 (en) * | 2001-03-27 | 2007-07-04 | Eisai R&D Management Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| EP1256573A1 (en) | 2001-05-09 | 2002-11-13 | Eisai Co., Ltd. | Process for producing stereoisomer of pyrrolidine derivative |
| RU2004110717A (en) * | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Quinuclidine derivatives, methods for their preparation and their use as both M2- and / or M3-muscarinic receptors |
| US7361671B2 (en) * | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| DE10225537A1 (en) * | 2002-06-10 | 2003-12-18 | Bayer Ag | N-alkylated thiazolium salts and process for their preparation |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| PL210065B1 (en) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| DE10334724A1 (en) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-biaryl |
| AR046276A1 (en) * | 2003-10-07 | 2005-11-30 | Renovis Inc | DERIVATIVES OF AMIDA AS LIGANDS OF ION CHANNELS AND PHARMACEUTICAL COMPOSITIONS AND METHODS THAT USE THEM. |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| KR20130083389A (en) | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | Heterocyclic compounds as janus kinase inhibitors |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| SG10201912411RA (en) | 2011-12-28 | 2020-02-27 | Univ California | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014060381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclic compounds as pesticides |
| JP2016503395A (en) | 2012-10-31 | 2016-02-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | Heterocyclic compounds as pest control agents |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2970196B1 (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (en) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | COMPOUNDS AND THEIR USES FOR HEMOGLOBIN MODULATION |
| KR20150132146A (en) | 2013-03-15 | 2015-11-25 | 글로벌 블러드 테라퓨틱스, 인크. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA202092627A1 (en) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
| FI3102208T4 (en) | 2014-02-07 | 2024-09-23 | Global Blood Therapeutics Inc | Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| MA41841A (en) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES |
| EP3303316B1 (en) | 2015-06-03 | 2020-01-29 | H. Hoffnabb-La Roche Ag | Ethynyl derivatives |
| WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (en) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE |
| TW202332423A (en) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| EP3853234B1 (en) | 2018-09-18 | 2025-04-23 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| ES2966707T3 (en) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Hemoglobin modulators for the treatment of sickle cell disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| US5135935A (en) | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| GB9127279D0 (en) | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
| JPH05310732A (en) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | Cinnoline-3-carboxylic acid derivative |
| GB9207961D0 (en) | 1992-04-10 | 1992-05-27 | Ici Plc | Heterocyclic derivatives |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| WO1995031458A1 (en) * | 1992-10-13 | 1995-11-23 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
| GB9226573D0 (en) | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
| IL109451A0 (en) | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| GB9412145D0 (en) | 1994-06-17 | 1994-08-10 | Zeneca Ltd | Heterocycles |
| JPH08134067A (en) | 1994-11-11 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | Quinuclidine derivative |
| JPH08269056A (en) | 1995-03-29 | 1996-10-15 | Chugai Pharmaceut Co Ltd | Quinuclidine derivative having squalene synthase inhibitory action |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US6150352A (en) | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
-
2000
- 2000-09-27 RU RU2002111344/04A patent/RU2266905C2/en not_active IP Right Cessation
- 2000-09-27 WO PCT/JP2000/006665 patent/WO2001023383A1/en not_active Ceased
- 2000-09-27 US US10/088,554 patent/US6599917B1/en not_active Expired - Fee Related
- 2000-09-27 EP EP00962889A patent/EP1217001B1/en not_active Expired - Lifetime
- 2000-09-27 AU AU74464/00A patent/AU782114B2/en not_active Ceased
- 2000-09-27 ES ES00962889T patent/ES2252063T3/en not_active Expired - Lifetime
- 2000-09-27 BR BR0014331-6A patent/BR0014331A/en not_active Application Discontinuation
- 2000-09-27 TW TW089119958A patent/TWI282794B/en not_active IP Right Cessation
- 2000-09-27 NZ NZ517788A patent/NZ517788A/en not_active IP Right Cessation
- 2000-09-27 DK DK00962889T patent/DK1217001T3/en active
- 2000-09-27 JP JP2001526535A patent/JP4206212B2/en not_active Expired - Fee Related
- 2000-09-27 CN CNB00813541XA patent/CN100334085C/en not_active Expired - Fee Related
- 2000-09-27 CA CA002385995A patent/CA2385995C/en not_active Expired - Fee Related
- 2000-09-27 IL IL14863100A patent/IL148631A0/en unknown
- 2000-09-27 DE DE60024651T patent/DE60024651T2/en not_active Expired - Lifetime
- 2000-09-27 HU HU0203514A patent/HUP0203514A3/en unknown
- 2000-09-27 KR KR1020027003952A patent/KR100694687B1/en not_active Expired - Fee Related
- 2000-09-27 AT AT00962889T patent/ATE312100T1/en not_active IP Right Cessation
- 2000-09-27 MX MXPA02003167A patent/MXPA02003167A/en active IP Right Grant
-
2002
- 2002-03-12 IL IL148631A patent/IL148631A/en not_active IP Right Cessation
- 2002-03-26 NO NO20021528A patent/NO328218B1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002111344A (en) | A quinuclidine compound and a medicament containing the compound as an active ingredient | |
| AU736206B2 (en) | Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives | |
| RU2209813C2 (en) | Derivatives of pyridazine, medicinal agents based on thereof and method for treatment of arthritis | |
| RU2213089C2 (en) | Monocyclic benzamides of derivatives of 3- or 4-substituted 4-(aminomethyl)piperidine, methods for their preparing, pharmaceutical composition, method for its preparing, derivative of carboxylic acid | |
| KR920009815A (en) | Aminocoumaran Derivatives, Methods of Making and Uses | |
| MA27596A1 (en) | BENZOCONDENSED HETEROARYLAMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR THEIR USE | |
| RU2004119406A (en) | 5-SULFANIL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR APPLICATION AS A MEDICINAL PRODUCT | |
| HUP0001062A2 (en) | Pharmaceutical compositions of phosphinic acid derivatives having naaladase inhibitor acivity | |
| JP2002520323A5 (en) | ||
| KR100214453B1 (en) | Inhibitor for restenosis after percutaneous coronary arterioplasty | |
| ATE164575T1 (en) | SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS | |
| RU2005120780A (en) | COMPOUNDS WITH CONDENSED 1,3-DIHYDROIMIDAZOLE CYCLE | |
| JP2006514991A (en) | New pharmaceutical combination | |
| ATE128623T1 (en) | AGENT FOR IMPROVING DRUG EFFECTS FOR ANTITUMOR DRUGS. | |
| JP2022539523A (en) | cannabinoid conjugate molecule | |
| RU2002111866A (en) | Derivatives of N-substituted indole-3-glyoxylamide - an antitumor drug and an agent that suppresses angiogenesis (options), a pharmaceutical composition and an antitumor drug (options) | |
| DE60139639D1 (en) | SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE | |
| KR900003127A (en) | cardiac | |
| NO176840C (en) | Analogous Procedure for Preparation of 2,9-Disubstituted-4H-Pyrido [1,2-α-Pyrimidin-4-One | |
| JPWO2006088193A1 (en) | Antitumor agent | |
| JPH03503525A (en) | Optically pure R-(-)-nigludipine and its derivatives for the treatment of tumor diseases | |
| EE03296B1 (en) | Hydroxymic acid derivatives, pharmaceutical compositions containing them and process for their preparation | |
| JP2004533462A (en) | Organic nitrate-based compounds for the treatment of vasculopathy | |
| JP4045099B2 (en) | 20-HETE producing enzyme inhibitor | |
| HUP0004900A2 (en) | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient |